In September 2024, Journal of Practical Hepatology and Journal of Clinical Hepatology (both are listed as the key magazine of China technology), published the Multidisciplinary Expert Consensus on the Prevention and Treatment of Inflammatory Liver Injury with Bicyclol.

Inflammatory liver injury is the initiating factor for various chronic liver diseases. The diagnosis and treatment of liver injury often require multidisciplinary discussions and joint decision-making. The preparation of the Consensus is organized by the Hepatology Group of the Chronic Disease Management Branch of the China Medicinal Biotechnology Association. Domestic experts from relevant disciplines, based on the guidelines/consensus/clinical pathways and evidence-based medicine for liver disease diagnosis and treatment with reference to the clinical practice in China, summarize the progress of the multidisciplinary clinical application of Bicyclol in the prevention and treatment of inflammatory liver injury, and form 15 recommendations. The goal is to improve the reasonable and standardized application of Bicyclol in clinical practice and the prevention and treatment of inflammatory liver injury in each discipline.

At present, Bicyclol has been recommended in 3 Russian guidelines and 60 Chinese  guidelines, clinical pathways and consensuses including the Guidelines for the Prevention and Treatment of Chronic Hepatitis B, Guidelines of Prevention and Treatment for Alcoholic Liver Disease, Guidelines for Diagnosis and Management of Drug-induced Liver Injury, Guidelines for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Diseases, and Guidelines for Diagnosis and Treatment of Primary Hepatic Carcinoma.

Link: http://manu43.magtech.com.cn/Jwk_sygzb/CN/10.3969/j.issn.1672-5069.2024.05.005